Evidence map›Paper›PMID 37101182›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.

Christopher B Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Cody Peer, William D Figg, Tyler Yin, Nicole Houston, Ann McCoy and 13 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Targeting T regulatory (TCancer drug resistance (Alhambra, Calif.) · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 2 countries.

Christopher B Cole *Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Maria Pia Morelli *Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Massimo FantiniPrecision Biologics, Inc, Bethesda, MD, USA. massimo.fantini@precision-biologics.com.ORCID http://orcid.org/0000-0002-8164-2587
Markku MiettinenLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Patricia FetschLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cody PeerClinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
William D FiggClinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Tyler YinClinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Nicole HoustonWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ann McCoyWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Stanley LipkowitzWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Alexandra ZimmerWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jung-Min LeeWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Miroslava PavelovaWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Erin N VillanuevaWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kathryn TrewhittWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
B Brooke SolarzWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Maria FergussonWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sharon A MavroukakisPrecision Biologics, Inc, Bethesda, MD, USA.
Anjum ZakiPrecision Biologics, Inc, Bethesda, MD, USA.
Kwong Y TsangPrecision Biologics, Inc, Bethesda, MD, USA.
Philip M ArlenPrecision Biologics, Inc, Bethesda, MD, USA.
Christina M AnnunziataWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. annunzic@mail.nih.gov.
National Institutes of Health · USPrecision BioLogic (Canada) · CA

Funding

Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZICSC006537 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$14.4M
Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37101182
PMCPMC10131449
OpenAlexW4367052531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.